Pages that link to "Q37719683"
Jump to navigation
Jump to search
The following pages link to Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review (Q37719683):
Displaying 50 items.
- Rituximab for treating inhibitors in people with inherited severe hemophilia (Q24186623) (← links)
- Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (Q24187021) (← links)
- Rituximab for treating inhibitors in children with hemophilia (Q24197700) (← links)
- Immune mechanisms involved in the development and eradication of anti-factor VIII alloantibodies in hemophilia (Q26822663) (← links)
- Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity (Q26866323) (← links)
- Switching treatments in haemophilia: is there a risk of inhibitor development? (Q27001016) (← links)
- Present and future challanges in the treatment of haemophilia: a clinician's perspective (Q27026137) (← links)
- FVIII inhibitors: pathogenesis and avoidance (Q27027224) (← links)
- Different impact of factor VIII products on inhibitor development? (Q28075679) (← links)
- Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more (Q30234910) (← links)
- SIPPET: methodology, analysis and generalizability (Q30235225) (← links)
- The current state of adverse event reporting in hemophilia. (Q30239952) (← links)
- The safety of pharmacologic options for the treatment of persons with hemophilia (Q30249200) (← links)
- A new recombinant factor VIII: from genetics to clinical use. (Q30370282) (← links)
- Molecular diagnosis of haemophilia A at Centro Hospitalar de Coimbra in Portugal: study of 103 families--15 new mutations (Q30403462) (← links)
- Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A. (Q30958570) (← links)
- Current and evolving features in the clinical management of haemophilia (Q33708976) (← links)
- Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice (Q34059678) (← links)
- Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice (Q34157402) (← links)
- Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy (Q34416394) (← links)
- The past and future of haemophilia: diagnosis, treatments, and its complications. (Q34514907) (← links)
- Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011 (Q34580100) (← links)
- Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression (Q34784564) (← links)
- Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM. (Q35209354) (← links)
- Profile of efraloctocog alfa and its potential in the treatment of hemophilia A. (Q35565320) (← links)
- The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics (Q36236913) (← links)
- FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. (Q36243815) (← links)
- Structure of the Human Factor VIII C2 Domain in Complex with the 3E6 Inhibitory Antibody (Q36310238) (← links)
- New treatments in hemophilia: insights for the clinician (Q36612681) (← links)
- Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo (Q36897565) (← links)
- High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance. (Q37153668) (← links)
- Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study (Q37253340) (← links)
- Plasma-derived medicinal products self-sufficiency from national plasma: to what extent? (Q37370365) (← links)
- Key issues in inhibitor management in patients with haemophilia (Q37602415) (← links)
- Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment (Q37818493) (← links)
- Recombinant plasma proteins (Q37822845) (← links)
- Factor VIII inhibitors: a 50-year perspective (Q37876956) (← links)
- Factor VIII safety: plasma-derived versus recombinant products (Q37882787) (← links)
- Pharmacotherapy of haemophilia A (Q37891089) (← links)
- Joint protection in haemophilia. (Q37912258) (← links)
- Current Controversies in the Formation and Treatment of Alloantibodies to Factor VIII in Congenital Hemophilia A (Q37967312) (← links)
- Past, present and future of hemophilia: a narrative review (Q38007018) (← links)
- The modern treatment of haemophilia: a narrative review (Q38025882) (← links)
- Inhibitors: our greatest challenge. Can we minimize the incidence? (Q38070810) (← links)
- Alloantibodies in previously untreated hemophilia A patients: the role of environmental factors (Q38080144) (← links)
- Factor VIII inhibitors in hemophilia A: rationale and latest evidence (Q38101041) (← links)
- Factor VIII therapy for hemophilia A: current and future issues (Q38203350) (← links)
- Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors (Q38206855) (← links)
- Inhibitors - genetic and environmental factors (Q38206856) (← links)
- Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development (Q38224295) (← links)